About Seven Bridges
Seven Bridges is a leading biomedical data company specializing in software and data analytics to drive public and private healthcare research. The company enables researchers to extract meaningful insights from genomic and phenotypic data to advance precision medicine. Seven Bridges delivers end-to-end bioinformatic solutions that speed the path from raw experimental data to new treatments and diagnostics. The Seven Bridges Ecosystem consists of a compliant analytic platform, intelligently curated content, transformative algorithms, unprecedented access to federated datasets, and expert on-demand professional services. The platform is a cloud-based environment for conducting bioinformatic analyses at scale, serving as a central hub for teams to store, analyze, and jointly interpret their bioinformatic data. It co-locates analysis pipelines alongside the largest genomic datasets to optimize processing and allocates storage and compute resources on demand. The company serves researchers at the world's leading academic, biotechnology, clinical diagnostic, government, medical centers, and pharmaceutical entities. Seven Bridges helps organizations increase R&D efficiency, enhance the hypothesis resolution process, isolate critical biomarkers, and reduce computational workflow times and data storage costs. The company has been acquired by Velsera, which now offers all Seven Bridges products and services plus integrated solutions. Seven Bridges' innovative Graph Genome technology (GRAF) represents a breakthrough in representing and analyzing genomic information using graphs rather than strings of bases, allowing for unprecedented scale and accuracy in detecting genetic variation.
Clinical Focus
Medical conditions and clinical areas addressed by Seven Bridges.
Who It Serves
Milestones & Awards
Recent Milestones
Acquired by Velsera (date not specified). June 2020: Expanded GRAF offerings to support underrepresented populations and personalized graphs. June 2020: Partnership with Pancreatic Cancer Action Network. June 2020: Selected by CareDx for AlloSure 3.0 workflow support.
Awards & Recognition
Described as 'industry-leading bioinformatics ecosystem provider' and 'only major biomedical data analysis platform to operate with largest public infrastructure providers'
Key Partnerships
Social & Media
Follow on
Latest Updates
Teaching Introduction to Bioinformatics on the Cancer Genomics Cloud
Unveiling the Power of Connected Data: A Deep Dive into the Velsera Seven Bridges Platform
Advancing Multi-omics Analysis by Co-localizing Data, Workflows, and Computation
Advancing Alzheimer’s Treatment and Inclusive Research
Exploring the Science Behind Neoantigen Discovery from Mutations to Proteins
Company Details
- Headquarters
- Boston, MA, USA
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingSecurity & Compliance
Official Sources
Similar Companies in this Market
View all 60 →
23andMe
23andMe uses AI to analyze genetic data and provide personalized health summaries, risk assessments, and wellness recommendations based on genomic insights.
2bPrecise
AI-powered precision medicine platform for personalized treatment recommendations and genomic analysis.
ACT Genomics
AI-powered genomic analysis platform for precision medicine and personalized treatment recommendations.
Adaptive Biotechnologies
Adaptive Biotechnologies uses AI and machine learning to decode the immune system and identify disease-specific immune signatures for diagnosis and personalized treatment.
Ambry Genetics
Ambry Genetics is a leading clinical genetic testing laboratory specializing in hereditary cancer, rare disease, cardiology, and neurology testing. The company provides advanced genetic testing solutions with paired DNA/RNA analysis and comprehensive patient support programs.
Ataraxis
Ataraxis develops AI-native precision medicine tools that predict patient outcomes and treatment response in oncology. Their flagship product, Ataraxis Breast, provides clinically validated prognostic and predictive tests for breast cancer using multi-modal AI analysis of pathology images and clinical data.
Avenda Health
Avenda Health develops Unfold AI, an FDA-cleared artificial intelligence platform that creates 3D cancer estimation maps for prostate cancer. The technology analyzes standard-of-care data (MRI, biopsy, pathology, PSA) to visualize cancer location and extent, helping physicians make more informed treatment decisions and improve patient outcomes.
Base Genomics
Base Genomics appears to be a company in the Precision Medicine & Genomics space, but the scraped website content is empty or inaccessible, preventing detailed analysis of their offerings and target market.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.